SDOH Cancer

SESSION 2

Wednesday, August 28th 2024 at 11:00 am EDT

Speaker: 

Karen Winkfield

Karen M. Winkfield, MD, PhD
Professor of Radiation Oncology
Vanderbilt University Medical Center;
Ingram Professor of Cancer Research
Vanderbilt Ingram Cancer Center;
Professor of Medicine
Meharry Medical College;
Executive Director
Meharry-Vanderbilt Alliance
Nashville, Tennessee Los Angeles, California 

 

Scoll down to access the program LOG-IN window at the bottom of this page!
 

Target Audience

This activity is designed to meet the educational needs of case managers, nurses, pharmacists, pharmacy technicians, physicians, psychologists, social workers, dietitians, and other health care professionals who are interested in learning about the impact of social determinants of health in cancer care.

 

Learning Objectives

Upon completion of theactivity, participants should be better able to: 

  • Outline the role of SDOH in healthcare and treatment outcomes
  • Explain the role of SDOH in the prevention of various types of cancer in different populations
  • Identify and address barriers to the treatment of cancer associated with patient experience and SDOH
  • Identify and address barriers to integrating social care into cancer care
  • Describe the current payment landscape for addressing patient social needs (e.g. Z-codes)

 

Joint Accreditation Statement:

 

Jointly-Accredited-Provider-TM_1000x636

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and ViralEd, Inc. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

 


Physician Continuing Medical Education:

PACE designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Disclosure of Conflicts of Interest 

PACE requires every individual in a position to control educational content  to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling or distributing healthcare products by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no financial relationships.

 

Dr. Karen Winkfield

  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Gilead, Janssen, Viiv.

Disclosure of Unlabled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  


Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

 

 

FILL OUT THE FORM BELOW TO JOIN OUR PROGRAM

 

Social Determinants of Health (SDOH) in Cancer: Impact on Prevention, Treatment and Outcomes - SESSION 2
Your name *
Email address *
Degree/Profession *
Country *
How many participants are watching using your internet connection? *
 
* Required